Tag Archives: biosimilar

Lannett CY Q2 ‘21 (FY Q4 ’21) Earnings Update

Lannett hosted its CY Q2 ’21 (FY Q4 ’21) earnings call in which it provided brief updates to its biosimilar glargine U100 and biosimilar aspart development programs. Of note, Lannett now anticipates filing the bs-glargine BLA in H1 ’23 (previously “later in 2022”) with a US launch planned for H1 ’24 (previously 2023). Below, FENIX provides highlights and insights from the call.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.